Central Lancashire Online Knowledge (CLoK)

Title	Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: A hypothesis
Type	Article
URL	https://clok.uclan.ac.uk/35464/
DOI	https://doi.org/10.1016/j.mehy.2020.110393
Date	2020
Citation	Olsen, Ingar and Singhrao, Simarjit Kaur (2020) Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: A hypothesis. Medical hypotheses. ISSN 0306-9877
Creators	Olsen, Ingar and Singhrao, Simarjit Kaur

_____

Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: A hypothesis

Ingar Olsen[1], Sim K. Singhrao[2]

Ingar Olsen

ingar.olsen@odont.uio.no

[1]*Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway*

[2]*Brain and Behavior Centre, Faculty of Clinical and Biomedical Sciences, School of Dentistry, University of Central Lancashire, Preston, UK*

ABSTRACT

Recently it has been reported that reduced levels of salivary lactoferrin (LF) can be a plausible biomarker for amyloid beta (Aβ) accumulation as in the brain of Alzheimer's disease (AD) brains. This could mean that reduced levels of salivary LF act as a trigger for oral dysbiosis and that low LF levels could change the oral microbiota. A chemical change in the composition of saliva has not yet been considered as a cause for microbial dysbiosis but does present an opportunity to view oral dysbiosis as a plausible contributory factor in the development of AD pathophysiology. Oral dysbiosis has largely been reported as a result of inadequate oral hygiene and dry mouth in elderly subjects. Here we discuss if the deficiency of LF in saliva and gingival fluid of AD patients can facilitate proliferation of oral pathogens, and as a result their spread elsewhere in the body. Additionally, we ask if LF in the AD brain could be overexposed as a result of chronic infection. Together these outcomes will indicate if reduced levels of salivary LF can act as a trigger of oral dysbiosis.

30   Saliva

31   Brain

32   *Porphyromonas gingivalis*

33   Gingipains

34   Dysbiosis

35

36   **Introduction**

37   On the question of whether Alzheimer's disease (AD) is an infectious (communicable)

38   disease the research of Olsen and Singhrao [1] and Singhrao and Harding [2] support the

39   plausibility of AD being a polymicrobial dysbiosis of the host's microbiome.

40   Inadequate oral hygiene and dry mouth are accepted reasons for oral dysbiosis.

41   However, a change in the composition of saliva has not previously been considered as a cause

42   for microbial dysbiosis. The reasons for dysbiosis in a host's oral microbiome could be due to

43   unknown reasons whilst including those already linked to poor oral hygiene and xerostomia.

44   Carro et al. [3], using mass spectrometry and ELISA, it was demonstratedshowed for the first

45   time that early diagnosis of mild cognitive impairment (MCI) and subsequent AD can be

46   associated with impairment of salivary lactoferrin (LF). Later, Gonzáles-Sánchez et al. [4]

47   suggested that in salivary deficiency of LF, amyloid beta (Aβ) could be a biomarker of AD as

48   it correlates with the Aβ load in the brain following its visualization with amyloid-Position-

49   Emission Tomography (PET) neuroimaging. We hypothesize that salivary LF deficiency may

50   act as an unknown trigger of oral microbial dysbiosis. LF is a glycoprotein present in the

51   human saliva. It is also found in secretions such as milk, tears and gingival fluid, and in cells

52   like neutrophils [5] and has a broad spectrum antimicrobial activity. Being an antimicrobial

53   peptide, LF is considered part of the first line or innate immune defense against infections in

54   man [6] as it targets bacteria, viruses, fungi, yeasts and protozoa. LF is also an iron chelator

55   and hence prevents iron deposition. It has the ability to block aggregation of both Aβ and

56   phosphorylated tau, and rescues neuronal damage in AD brains [7, 8]. For a summary of the

57   biological functions of LF, see Table 1.

58   When Aβ accumulation reaches a plateau possibly from both local and peripheral Aβ

59   pools [9], it indicates the MCI stage or prodromal AD. Following this stage, the pathological

60   cascade of progressive AD takes over. As an antimicrobial peptide, LF can modulate immune

61   reactions and inflammation (for a review see Farah et al. [10]). A plethora of reports

62 implicate the immune system as a major player in AD manifestation [11-14]. There is

63 probably an association between systemic infection and AD where salivary LF is down-

64 regulated like several other factors of systemic immunity [6].

65   The present paper will discuss (1) if deficiency of LF in saliva and gingival fluid of

66 AD patients can facilitate proliferation of oral pathogens, (2) if this proliferation can result in

67 transfer of oral pathogens and tissue inflammatory mediators to the brain, and (3) if LF in the

68 brain of AD patients could be overexposed as a result of chronic infection.

69

70 **Decreased salivary lactoferrin is specific to Alzheimer's disease**

71   In a recent study Gonzáles-Sánchez et al. [4], who examined the relationship between

72 salivary levels of LF and cerebral Aβ load by using PET neuroimaging, found that LF could

73 be used to detect MCI or prodromal AD and distinguish AD from other frontotemporal

74 dementias (FTDs), with sensitivies and specificities over 87% and 91%, respectively. This

75 study also indicated that LF represents one of the main first lines of defense against pathogens

76 and confirmed previous findings that there is an association between AD and the immune

77 system, and brain infections with bacteria, viruses and/or yeasts. These microorganisms can all

78 be related to increased signs of neuroinflammation in the brain [1, 4, 15]. The study of

79 Gonzáles-Sánchez et al. [4] was the first to show the diagnostic performance and specificity

80 of a single saliva-based biomarker for detecting MCI and AD. It demonstrated that salivary

81 LF levels are reduced in AD and, noteworthy, are associated with the amyloid-PET imaging

82 profile, even in the prodromal stage. An independent cross-sectional study confirmed

83 simultaneously the presence of low saliva LF levels in AD, as shown previously [3].

84

85 **Low salivary lactoferrin might be an effect of immunological disturbances in**

86 **Alzheimer's disease**

87   AD subjects have long been recognized to suffer from poor oral health and xerostomia

88 which is thought to be a side effect of their medication. However, this view is changing as

89 Bermeji-Pareija et al. [6] proposed that reduced levels of salivary LF might be an effect of

90 immunological disturbances associated with AD. Two pathways could be responsible for this:

91 first, AD could be a systemic disorder (or disorders) related to early immunological and low

92 inflammatory changes, and secondly, systemic immunity changes in AD manifestation could

93   be a downstream effect of early AD brain involvement. The authors emphasized that the

94   general acceptance of low LF as an early AD biomarker would rely on validation of LF levels

95   in other clinical and population-based studies.

96

97   **Deficiency in salivary lactoferrin in Alzheimer's disease could contribute to dysbiosis of**

98   **the oral microbiota**

99   LF is secreted by the serous acinar cells of the major and minor salivary glands. In

100 whole saliva it also originates from neutrophil granulocytes and from the gingival crevicular

101 fluid. LF plays an important role in regulating the oral microbiota and the inflammatory state

102 of the oral mucosa [16]. It contributes to the maintenance of symbiosis in the host-

103 microbiome relationship. In dysbiosis, however, certain bacteria are able to flourish at the

104 demise of others. Particularly the oral pathogen *Porphyromonas gingivalis* will take

105 advantage of iron released from haem in inflamed tissues, and increase in number (Figure 1).

106 This bacterium has a remarkable effect to initiate dysbiosis even in low concentration [17]. In

107 dysbiosis, levels of salivary LF are expected to increase whilst the body resolves

108 inflammation and restores symbiosis [18].

109   However, when LF levels are low, as seen in AD, dysbiosis is expected to proceed

110 freely. In a study on the subgingival microbiota of people with cognitive dysfunction

111 participants with periodontitis had a greater abundance of several bacteria: the highest log2-

112 fold changes were seen for *Porphyromonas* and *Peptostreptococcaceae* [19]. Even in aged

113 subjects with oral dryness, salivary levels of LF and chromogranin A were low [20] and this

114 may aid spread of oral bacteria to the brain.

115   Dysbiosis can also contribute to a dormant blood microbiome (atopobiosis) and

116 directly promote systemic inflammation through amyloidogenic formation and shedding of

117 inflammagens such as lipopolysaccharides (LPSs) [21]. Dormant, non-growing bacteria are

118 important features in AD. Their growth *in vivo* is usually limited by a lack of free iron and

119 this iron dysregulation could be an important factor in their resuscitation [22]. A simultaneous

120 iron dysregulation and microbial aberrations could affect the hematological system by

121 promoting fibrin amyloidogenesis and pathological clotting [23].

122

123 **Lactoferrin in the gingival crevicular fluid**

124　　　　LF is part of the gingival crevicular fluid secreted from the inflamed periodontium

125　　around teeth harboring supra- and sub-gingival biofilms. Studies have shown that LF can be a

126　　biofilm inhibitor of periodontopathic bacteria *in vitro* and *in vivo* [24]. These authors reported

127　　that LF reduced the established biofilm at physiological concentrations. The adjunct use of LF

128　　for the prevention and treatment of periodontal diseases has therefore been suggested [25]. LF

129　　was raised in stimulated whole saliva in subjects with "chronic" periodontitis where it

130　　correlated with probing pocket depths ≥ 6 mm [26]. In a study by Daspher et al. [27], LF

131　　inhibited *P. gingivalis* biofilm formation by 80% at concentrations above 0.625 µM. *P.*

132　　*gingivalis*, which is a Gram-negative anaerobic rod, is considered a keystone bacterium in

133　　periodontitis [28-30]. The antimicrobial protection exerted by LF could be reduced when it is

134　　present in low concentrations, as in AD. Maintaining the flow of saliva and the presence of

135　　antimicrobial substances are important to preserve oral health. As mentioned, in the older

136　　population salivary flow is often reduced, for example as a side effect of drug intake. This

137　　could predispose these persons to systemic infection with periodontal bacteria.

138

Periodontal bacteria can degrade lactoferrin by its proteases

140　　　　LF binds to a high-affinity receptor on periodontal bacteria such as *P. gingivalis,*

141　　*Prevotella intermedia* and *Prevotella nigrescens.* In the case of *P. gingivalis*, all strains

142　　completely degraded LF under the investigative conditions used, whereas only partial

143　　degradation was seen with *P. intermedia* and *P. nigrescens* [31]. The proteases (gingipains) of

144　　*P. gingivalis* may protect this bacterium against LF in periodontal and systemic sites and thus

145　　serve as important virulence factors. Alugupalli and Kalfas [32] found in an *in vitro* study

146　　that the degradation of LF was more extensive by *P. gingivalis* and *Capnocytophaga*

147　　*sputigena,* slow by *Capnocytophaga ochracea, Aggregatibacter* (*Actinobacillus*)

148　　*actinomycetemcomitans* and *P. intermedia*, and very slow or absent by *P. nigrescens,*

149　　*Campylobacter rectus*, *Campylobacter sputorum*, *Fusobacterium nucleatum* ssp. *nucleatum*,

150　　*Capnocytophaga gingivalis*, *Tannerella* (*Bacteroides*) *forsythia* and *Peptostreptococcus*

151　　*micros.* All the *P. gingivalis* strains tested degraded LF. The degradation was sensitive to the

152　　protease inhibitors cystatin C and albumin. These studies indicated that periodontopathogens

153　　can degrade LF. This could facilitate proliferation of some of the most virulent bacteria in

154　　periodontal infections, and possibly promote AD by systemic spread of these bacteria and

155　　their inflammagens to the brain. Inflammagens from *P. gingivalis* such as gingipain R1

156　　(RgpA) and LPS have been reported to have major effects on blood clot morphology and

157 mechanics thereby driving systemic inflammation [33]. Interestingly, intake of tablets

158 containing LF (60 mg/d) and lactoperoxidase (7.8 mg/d) improved gingival inflammation and

159 oral health-related quality of life in healthy adults [34] supporting the concept that low levels

160 of LF are indicators of dysbiosis.

161

162 *Porphyromonas gingivalis* **in Alzheimer's disease**

163   Recent work has increasingly focused on AD as a microbial disease, for example

164 Sochocka et al. [15] and Itzaki et al. [35]. In the oral microbiota, *P. gingivalis* has attracted

165 much attention for its possible role in AD (Figure 1) [13, 36-40]. However, it may take a long

166 time for *P. gingivalis* to promote development of AD. Thus, Sparks Stein et al. [41], Tzeng et

167 al. [42] and Chen et al. [43] found that gingivitis and chronic periodontal disease could take

168 up to 10 years for AD to occur. This may also be the time it takes for Aβ to reach a plateau to

169 become MCI.

170

171 **Low salivary lactoferrin could promote transfer of oral bacteria and tissue**

172 **inflammatory mediators to the brain**

173   Each time we chew on a periodontitis-affected tooth there will be a bacteremia. During

174 a day this can last for a total of 3 hours [44]. The spectrum of oral bacteria in this bacteremia

175 is wide [45] (Figure 1). Also viruses, bacteriophages and yeasts in the periodontal pocket

176 could follow the bacteria into the blood stream as well as inflammatory mediators from the

177 inflamed periodontal tissues [1]. In an elderly person with deteriorated blood-brain barrier,

178 periodontal microorganisms and inflammatory mediators can reach the brain. Several other

179 ways than the blood stream can also be used by oral microorganisms for brain transfer [1].

180 Periodontal pathogens like *P. gingivalis* and their main virulence factors, like LPS and

181 gingipains have been demonstrated in the brain of AD patients and in animal models of AD

182 [37, 46-48]. It is therefore highly plausible that low salivary LF levels, by reducing innate

183 immunity, can promote dissemination of periodontitis-related microorganisms and

184 inflammatory tissue mediators to the brain. In addition, salivary LF is transferred into the

185 brain via the sublingual route [49]. Low levels of salivary LF may therefore affect the

186 concentration of LF in the AD brain.

187

High concentrations of lactoferrin have initially a protective effect on Alzheimer's disease

LF has been considered to have a beneficial effect in AD subjects, but the mechanism is unclear. A possible way could be through its ability to alleviate the AD pathological cascade and cognitive decline via modulation of the p-Akt/PTEN (phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (PKB or Akt)/phosphatase and tensin homolog (PTEN) pathway [50]. These authors reported a possible protective mechanism of post-LF administration for 3 months in AD patients' changes in this pathway. LF probably caused this by affecting key players of inflammation and oxidative stress involved in AD pathology. It should also be mentioned that iron dysregulation, which is seen in AD, contributes to oxidative stress [21]. LF could reduce inflammation and stress by binding iron.

The spread of microorganisms to the brain is controlled by several factors, including LF which, as mentioned, also has an anti-inflammatory effect, especially associated with the down-regulation of pro-inflammatory cytokines like IL-6. This reduces local and/or systemic inflammation [51]. Excessive iron contributes to the deposition of Aβ and the formation of neurofibrillary tangles, which in turn, promotes the development of AD [7]. LF blocks Aβ-aggregation, tauopathy spread and neuronal damage [7]. It also acts as an iron-binding protein and is strongly up-regulated in the brains of patients with AD [52]. In transgenic mice with AD these authors used double-immunofluorescence labelling with antibodies directed against Aβ and LF, and found LF depositions localized to Aβ plaques and regions of amyloid angiopathy. Both the intensity and number of LF-positive depositions increased with age. The up-regulation of LF in the brains of both AD patients and transgenic mice with AD indicated an important protective role for LF in infected AD-brain tissue [53]. It is tempting to speculate that the high consumption of LF in AD could lead to reduced LF levels over time, particularly when AD is promoted by long-term chronic infection. Interestingly, Bermejo-Pareja et al. [6] suggested that LF was downregulated in the saliva of AD patients like several other factors of systemic immunity.

Concluding remarks

217   If LF is a trigger of oral dysbiosis this makes it plausible that it could be a factor in the

218   etiology or pathophysiology of AD. It is remarkable that the levels of LF are increased in the

219   brains of AD patients, at least initially, and reduced in their whole saliva. It may be that the

220   long-term fight against chronic infection in the brain tends to reduce the level of LF. The

221   latter scenario could aggravate brain infection. It is also possible that low levels of LF in the

222   whole saliva of AD patients may affect the LF concentration in the brain since salivary LF is

223   transferred into the brain via the sublingual route. In mice dietary LF supplementation

224   prevented memory impairment and reduced Aβ generation, and post LF-administration for 3

225   months in AD patients alleviated the AD pathological cascade and cognitive decline by

226   modulating the p-Akt/PTEN pathway. Furthermore, tablets containing LF and lactoperoxidase

227   improved gingival inflammation and oral health-related quality of life in healthy adults

228   suggesting LF supplements may be a plausible therapy for AD subjects, together with

229   effective periodontitis prophylaxis and treatment to prevent systemic spread of periodontal

230   bacteria.

231   Another intriguing aspect is that *P. gingivalis*, which is a keystone bacterium in

232   periodontitis, and recently has been associated with AD, has the ability to reduce LF levels

233   through its gingipains. This could take place in the periodontal pocket, but could also occur in

234   the brain of AD patients where both *P. gingivalis* and its gingipains have been detected.

235   Noteworthy in this context is also the finding that *P. gingivalis* was the most powerful LF-

236   degrading bacterium of several periodontal pathogens tested *in vitro*. It is plausible that *P.*

237   *gingivalis*' effect on LF could be added to its wide capacity of immune suppression, acting

238   both in the periodontal pocket and in the AD brain. There are also other proteins and peptides

239   in saliva but their functions and interactions with the oral microbiome remain to be

240   determined. Clearly, when the level of whole saliva is reduced, its composition is changed and

241   this could promote dysbiosis and the risk of associated oral diseases such as caries, gingivitis,

242   periodontitis and fungal infections, and possibly AD. For now, Carro et al. [3] and Gonzáles-

243   Sánchez et al. [4] have highlighted LF as an Aβ biomarker of AD, and the authors of the

244   current paper have suggested it to be a plausible trigger of oral dysbiosis. Further *in vivo*

245   research on LF and its functions in causing dysbiosis of host mechanisms in the periodontal

246   pocket and in the brain of AD patients is required to support our hypothesis.

247

250

Compliance with ethical standards

252   The authors have no relevant affiliations of financial involvement with any

253 organization or entity with a financial interest in or financial conflict with the subject matter

254 or materials discussed in the manuscript. This includes employment, consultancies, honoraria,

255 stock ownership or options, expert testimony, grants or patents received or pending, or

256 royalties.

257

References

259 1. Olsen I, Singhrao SK (2015) Can oral infection be a risk factor for Alzheimer's disease? J

260 Oral Microbiol 7: 2914

261 2. Singhrao SK, Harding A (2020) Is Alzheimer's disease a polymicrobial host microbiome

262 dysbiosis? Expert Rev Anti Infect Ther 18(4): 275-277

263 3. Carro E, Bartolomé F, Bermejo-Pareja F, Villarejo-Galende A, Molina JA, Ortiz P, Calero

264 M, Rabano A, Cantero JL, Gorka Orive G (2017) Early diagnosis of mild cognitive

265 impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimer's Dement

266 Diagnosis Assess Dis Monit 8: 131–138

267 4. González-Sánchez M, Bartolomé F, Antequera D, Puertas-Martín V, González P, Gómez-

268 Grande A, Llamas-Velasco S, Herrero-San Martín A, Pérez-Martínez D, Villarejo-Galende A,

269 Atienza M, Palomar-Bonet M, Cantero JL, Perry G, Orive G, Ibañez B, Bueno H, Fuster V,

270 Carro E (2020) Decreased salivary lactoferrin levels are specific to Alzheimer's disease.

271 EBioMedicine 57: 102834

272 5. Kell DB, Heyden EL, Pretorius E (2020) The biology of lactoferrin, an iron-binding

273 protein that can help defend against viruses and bacteria. Front Immunol 11: 1221

274 6. Bermejo-Pareja F, del Ser T, Valenti M, de la Fuente M, Bartolome F, Carro E

275 (2020) Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity

276 interactions. Alzheimer's Dement 16: 1196-1204

277 7. Liu J-L, Fan Y-G, Yang Z-S, Wang Z-Y, Guo C (2018) Iron and Alzheimer's disease:

278 From pathogenesis to therapeutic implications. Front Neurosci 12: 632

279   8. Olsen I (2020) Possible link between *Porphyromonas gingivalis* and amyloidosis in the
280   pathogenesis of Alzheimer's and Parkinson's disease. Int J Pathol 1(1): 1-12

281   9. Olsen I, Singhrao SK (2020) *Porphyromonas gingivalis* infection may contribute to
282   systemic and intracerebral amyloid-beta: implication for Alzheimer's disease onset. Expert
283   Rev Anti Infect Ther 1-4

284   10. Farah R, Hardy H, Salame Z, Fares Y, Ojcius DM, Najwane Said Sadier NS
285   (2018) Salivary biomarkers for the diagnosis and monitoring of neurological diseases.
286   Biomed J 41(2): 63-87

287   11. Rogers J, Luber-Narod J, Styren SD, Civin WH (1988) Expression of immune system-
288   associated antigens by cells of the human central nervous system: relationship to the
289   pathology of Alzheimer's disease. Neurobiol Aging 9: 339–349

290   12. McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989) Immune system response in
291   Alzheimer's disease. Can J Neurol Sci 16(4 Suppl): 516-527

292   13. Jevtic S, Sengar AS, Salter MW, McLaurin J (2017) The role of the immune system in
293   Alzheimer disease: Etiology and treatment. Ageing Res Rev 40: 84-94

294   14. Olsen I, Singhrao SK (2019) Is there a link between genetic defects in the complement
295   cascade and *Porphyromonas gingivalis* in Alzheimer's disease? J Oral Microbiol 12(1):
296   167648

297   15. Sochocka M, Zwolińska K, Leszek J (2017) The infectious etiology of Alzheimer's
298   disease. Curr Neuropharmacol 15(7): 996-1009

299   16. Lynge Pedersen AM, Belstrøm D (2019) The role of natural salivary defences in
300   maintaining a healthy oral microbiota. J Dent 80: S3-S12

301   17. Lamont RJ, Hajishengallis G (2015) Polymicrobial synergy and dysbiosis in inflammatory
302   disease. Trends Mol Med 21(3): 172-183

303   18. Berlutti F, Pilloni A, Pietropaoli M, Polimeni A, Valenti P (2011) Lactoferrin and oral
304   diseases: current status and perspective in periodontitis. Ann Stomatol (Roma) 2(3-4): 10-18

305   19. Holmer J, Aho V, Eriksdotter M, Paulin L, Pietiäinen M, Auvinen P, Schultzberg M,
306   Pussinen PJ, Buhlin K (2020) The subgingival microbiota of people with cognitive
307   dysfunction. J Oral Microbiol 12: submitted

308 20. Mizuhashi F, Koide K , Toya S, Takahashi M, Mizuhashi R , Shimomura H

309 (2015) Levels of the antimicrobial proteins lactoferrin and chromogranin in the saliva of

310 individuals with oral dryness. J Prosthet Dent 113(1): 35-38

311 21. Pretorius L, Kell DB, Pretorius E (2018) Iron dysregulation and dormant microbes as

312 causative agents for impaired blood rheology and pathological clotting in Alzheimer's type

313 dementia. Front Neurosci 12: 851

314 22. Pretorius E, Bester J, Kell DB (2016) A bacterial component to Alzheimer's-type

315 dementia seen via a systemic biology approach that links iron dysregulation and inflammagen

316 shedding to disease. J Alzheimers Dis 53(4): 1237-1256

317 23. Lipinski B, Pretorius E (2013) The role of iron-induced fibrin in the pathogenesis of

318 Alzheimer's disease and the protective role of magnesium. Front Hum Neurosci 7: 735

319 24. Wakabayashi H, Kondo I, Kobayashi T, Yamauchi K, Toida T, Iwatsuki K, Yoshie H

320 (2020) Periodontitis, periodontopathic bacteria and lactoferrin. Biometals 23(3): 419-424

321 25.Wakabayashi H, Yamauchi K, Kobayashi T, Yaeshima T, Iwatsuki K, Yoshie H (2009)

322 Inhibitory effects of lactoferrin on growth and biofilm formation of *Porphyromonas gingivalis*

323 and *Prevotella intermedia.* Antimicrob Agents Chemother 53(8): 3308-3316

324 26. Glimvall P, Wickström C, Jansson H (2012) Elevated levels of salivary lactoferrin, a

325 marker for chronic periodontitis? J Periodontal Res 47(5): 655-660

326 27. Dashper SG, Pan Y, Veith PD, Che Y-Y, Toh ECY, Liu SW, Cross KJ, Reynolds EC

327 (2012) Lactoferrin inhibits *Porphyromonas gingivalis* proteinases and has sustained biofilm

328 inhibitory activity. Antimicrob Agents Chemother 56(3): 1548-1556

329 28. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr (1998) Microbial

330 complexes in subgingival plaque. J Clin Periodontol 25(2): 134-144

331 29. Hajishengallis G, Darveau RP, Curtis MA (2012) The Keystone-Pathogen Hypothesis.

332 Nat Rev Microbiol 10: 717-725

333 30. Darveau RP, Hajishengallis G, Curtis MA (2012) *Porphyromonas gingivalis* as a potential

334 community activist for disease. J Dent Res 91: 816-820.

335 31. de Lillo A, Teanpaisan R, Fierro JF, Douglas CW (1996) Binding and degradation of

336 lactoferrin by *Porphyromonas gingivalis*, *Prevotella intermedia* and *Prevotella nigrescens*.

337 FEMS Immunol Med Microbiol 14(2-3): 135-143

338 32. Alugupalli KR, Kalfas S (1996) Degradation of lactoferrin by periodontitis-associated
339 bacteria. FEMS Microbiol Lett 145(2): 209-214

340 33. Nunes JM, Fillis T, Page MJ, Venter C, Launcry O, Kell DB, Windberger U, Pretorius E
341 (2020) Gingipain R1 and lipopolysaccharide from *Porphyromonas gingivalis* have major
342 effects on blood clot morphology and mechanics. Front Immunol 11: 1551

343 34. Nakano M, Yoshida A, Wakabayashi H, Tanaka M, Yamauchi K, Abe F, Masuda Y
344 (2019) Effect of tablets containing lactoferrin and lactoperoxidase on gingival health in
345 adults: A randomized, double-blind, placebo controlled clinical trial. J Periodontal Res
346 54(6):702-708

347 35. Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter
348 C, Clerici M, Cosby SL, Tredici KD, Field H, Fulop T, Grassi C, Griffin WST, Haas
349 J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lövheim H, Mancuso
350 R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg
351 T, Tabet N, Taylor-Robinson S-D, Whittum-Hudson JA (2016) Microbes and Alzheimer's
352 disease. J Alzheimers Dis 51(4): 979-984

353 36. Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME, Le K, Aljewari
354 HW, O'Brien-Simpson NM, Reynolds EC, Watanabe K (2018) Chronic oral application of a
355 periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta
356 production in wild type mice. PLoS One 13(10): e0204941

357 37. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen
358 M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder
359 MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds
360 EC, Faull RLM, Curtis MA, Dragunow M, Potempa J (2019) *Porphyromonas gingivalis*
361 in Alzheimer's disease brains: evidence for disease causation and treatment with small-
362 molecule inhibitors. Sci Adv 5(1): eaau3333

363 38. Olsen I, Singhrao SK (2019) Poor oral health and its neurological consequences:
364 Mechanisms of *Porphyromonas gingivalis* involvement in cognitive dysfunction. Curr Oral
365 Health Rep 6: 120-129

366 39. Singhrao SK, Olsen I (2019) Assessing the role of *Porphyromonas gingivalis* in
367 periodontitis to determine a causative relationship with Alzheimer's disease. J Oral Microbiol
368 11: 1563405

40. Olsen I, Singhrao SK (2020) Interaction between genetic factors, *Porphyromonas gingivalis* and microglia to promote Alzheimer's disease. J Oral Microbiol 12: 1820834

41. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D 3rd (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 8: 196–203

42. Tzeng N-S, Chung C-H, Yeh C-B, Huang R-Y, Yuh D-Y, Huang S-Y, Lu R-B, Chang H-A, Kao Y-C, Chiang W-S, Chou Y-C, Chien W-C (2016) Are chronic periodontitis and gingivitis associated with dementia? A nationwide, retrospective, matched-cohort study in Taiwan. Neuroepidemiology 47: 82–93

43. Chen C-K, Wu Y-T, Chang Y-C (2017) Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study. Alzheimers Res Ther 9: 56

44. Tomás I, Diz P, Tobías A, Scully C, Donos N (2012) Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. J Clin Periodontol 39: 213-228

45. Bahrani-Mougeot FK, Paster BJ, Coleman S, Ashar J, Barbuto S, Lockhart PB (2008) Diverse and novel oral bacterial species in blood following dental procedures. J Clin Microbiol 46(2): 2129-2132

46. Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S (2013) Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimers Dis 36(4): 665-677

47. Poole S, Singhrao SK, Chukkapalli S, Rivera M, Velsko I, Kesavalu L, Crean S (2015) Active invasion of *Porphyromonas gingivalis* and infection-induced complement activation of ApoE$^{-/-}$ mice brains. J Alzheimers Dis 43(1): 67-80

48. Siddiqui H, Eribe ERK, Singhrao SK, Olsen I (2019) High throughput sequencing detects gingivitis and periodontal oral bacteria in Alzheimer's disease autopsy brains. Neuro Res 1(1): 3

49. Hayashi T, To M, Saruta J, Sato C, Yamamoto Y, Kondo Y, Shimizu T, Kamata Y, Tsukinoki K (2017) Salivary lactoferrin is transferred into the brain via the sublingual route. Biosci Biotechnol Biochem 81(7): 1300-1304

399   50. Mohamed WA, Salama RM, Schaalan MF (2019) A pilot study on the effect of lactoferrin

400   on Alzheimer's disease pathological sequelae: Impact of the p-Akt/PTEN pathway. Biomed

401   Pharmacother 111: 714-723

402   51. Lepanto MS, Rosa L, Paesano R, Valenti P, Cutone A (2019) Lactoferrin in aseptic and

403   septic inflammation. Molecules 24(7): 1323

404   52. Wang L, Sato H, Zhao S, Tooyama I (2010) Deposition of lactoferrin in fibrillar-type

405   senile plaques in the brains of transgenic mouse models of Alzheimer's disease. Neurosci Lett

406   481(3): 164-167

407   53. Abdelhamid M, Jung C-G, Zhou C, Abdullah M, Nakano M, Wakabayashi H , Abe

408   F, Michikawa M (2020) Dietary lactoferrin supplementation prevents memory impairment

409   and reduces amyloid-β generation in J20 mice. J Alzheimers Dis 74(1): 245-259

410

411

Figure 1. Schematic to show how reduced levels of salivary lactoferrin (LF) may be a

plausible trigger of oral biofilm dysbiosis. Oral dysbiosis has largely been seen as a result of

inadequate oral hygiene and xerostomia in elderly subjects. Once the LF level begins to

415   decrease, this becomes a vicious cycle for sustained dysbiosis. From here *P. gingivalis* can

416   spread, via bacteremia, to disparate body organs, for example the brain. This destabilize the

417   immune balance, and inflammatory disease such as AD (Alzheimers'disease) develops.

418

419

420

421

422

423

424

425

426

427

428 **Table 1.** Physiological properties of lactoferrin (adopted from [5])

Physiological actions	Mechanisms
Iron-binding protein	Iron absorption, transport and sequestration
Host defence	Activities against pathogens: antibacterial, antifungal, antiparasitic, antiviral
	Anti-inflammatory and alarming
	Anti-endotoxin
	Anticancer
	Inhibition of prion accumulation
Host activities	Brain development and neuroprotection: alleviating psychological stress
	Bone formation
	Gastrointestinal development
	Immune actions (innate and adaptive): enhancer and modulator
	Wound healing
Metabolic	Adipocytes differentiation
	Antioxidant: inhibiting lipid peroxidation
	Association with other proteins: osteopontin and others
	Decreasing vasoconstriction
	Enzymatic activities
	Glucose regulation (decreasing hyperglycemia)
	Gut microbiota modulation
	Transcriptional regulator
Miscellaneous	Compounds or metabolites carrier (mainly into brain)
	Vaccine adjuvant
	Possible sAD biomarker

429